Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

Qing Kay Li, M.D., Ph.D.

Headshot of Qing Kay Li
  • Professor of Pathology

Languages: English, Chinese


Cytopathology, Pathology

Research Interests

Genetic biomarkers; Lung cancer; Early detection of lung and prostate cancer more


The Johns Hopkins Hospital

600 N. Wolfe Street
Sheikh Zayed Tower 612B
Baltimore, MD 21287 map
Phone: 410-955-9790 | Fax: 410-614-9556

Johns Hopkins Outpatient Center

601 N. Caroline St.
Baltimore, MD 21287 map
Phone: 410-955-9790

Johns Hopkins Bayview Medical Center

4940 Eastern Avenue
Baltimore, MD 21224 map
Phone: 410-955-9790


Dr. Qing Kay Li is a professor of pathology at the Johns Hopkins University School of Medicine. She has the American Board of Pathology certification in anatomic and clinical pathology, and subspecialty certification in cytopathology.  Her areas of clinical expertise include surgical pathology and cytopathology.  

Dr. Li received her medical degree from Tianjin Medical University, and completed her pathology resident training at Albany Medical College, surgical pathology fellowship at University Hospital of Cleveland, and cytopathology fellowship at the University of Michigan Hospital. She also had a PhD and cell biology fellowship training at the Cleveland Clinic Foundation. 

Dr. Li is also a faculty member and co-PI at the Johns Hopkins Biomarker Discovery Center.  Her research interests is focusing on the application of advanced cellular and molecular techniques to the field of cytopathology and cancer biology, particularly in the field of early detection of lung and prostate cancer.  

Dr. Li also serves as editorial board members for several journals, committee member of the American Society of Cytopathology, and study sections of government agents and private organizations.  She has more than 80 publications and book chapters.  Her work has been presented at many national/international meetings.  Dr. Li is also the co-editor of “Diagnostic Cytopathology Board Review and Self-Assessment”. more


  • Professor of Pathology
  • Professor of Oncology

Departments / Divisions



  • MD; Tianjin Medical University (1983)


  • Pathology; Albany Medical Center-SUNY (2004)
  • Internal Medicine; Tianjin Medical University (1987)


  • Internal Medicine; Tianjin Medical University (1988)
  • Pathology; University Hospitals Cleveland Medical Center (2006)
  • Cytopathology; University of Michigan Health System (2005)

Board Certifications

  • American Board of Pathology (Anatomic & Clinical Pathology) (2005)
  • American Board of Pathology (Cytopathology) (2007)

Research & Publications

Research Summary

Dr. Qing Kay Li’s research focuses on the early detection of lung and prostate cancers and ways to separate aggressive from non-aggressive tumors using state-of-the-art molecular tools.

Recently, Dr. Li and her team identified hundreds of protein and genetic biomarkers in the airway fluid (bronchoalveolar lavage) from lung cancer patients. Their preliminary data shows that these protein and genetic biomarkers have the potential to improve the accuracy of current lung cancer screening tests and could play a role in the early detection of lung cancers, particularly in patients with small lung nodules.

Selected Publications

Bertotti A, Papp E, Jones S, Adleff V, Sausen M, Anagnostou V, Phallen J, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA, Jr., Trusolino L, Velculescu VE. The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer. Nature. 2015;526:263-267.

Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu NL, Gills JJ, Dennis PA*. Control of PD-L1 expression by oncogenic activation of the AKT/mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76:227-238.

Lilo MT, Allison D, Wang Y, Ao MH, Gabrielson E, Geddes S, Zhang H, Askin F, Li QK. Expression of P40 and P63 in lung cancers using fine needle aspiration (FNA) cases. Understanding clinical pitfalls and limitations. J Am Soc Cytopathol. 2016;5:123-132.

Allison DB, Lilo MT, Geddes S, Pallavajjalla A, Askin F, Gabrielson E, Zheng G, Li QK. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic NSCLC: a retrospective study of 115 FNA cases. Cancer Cytopathol. 2016;124:485-492.

Sharma R, Wang Y, Gurda GT, Geddes S, Gabrielson E, Askin F, Li QK. Utility of the novel triple marker (combination of TTF, Napsin-A and p40) in the subclassification of non-small cell lung carcinomas (NSCLC) using fine needle aspiration (FNA) materials. Hum Pathol. 2016;54:8-16.

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile
back to top button